Type of TP53 mutation is not prognostic in high grade serous ovarian carcinoma, but presence is prognostic in endometriosis-associated carcinomas

被引：0
|
作者：
Brett, Mary Anne [1 ]
Ramus, Susan [2 ]
Brenton, James [3 ]
Kobel, Martin [1 ]
机构：
[1] Univ Calgary, Calgary, AB, Canada
[2] Univ New South Wales, Sydney, NSW, Australia
[3] Univ Cambridge, Cambridge, England
来源：
LABORATORY INVESTIGATION | 2019年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
1006
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
    Tuna, Musaffe
    Ju, Zhenlin
    Yoshihara, Kosuke
    Amos, Christopher I.
    Tanyi, Janos L.
    Mills, Gordon B.
    BRITISH JOURNAL OF CANCER, 2020, 122 (03) : 405 - 412
  • [32] TP53 mutations as a biomarker for high-grade serous ovarian cancer: are we there yet?
    Oien, Derek B.
    Chien, Jeremy
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S264 - S268
  • [33] Clinical relevance of TP53 hotspot mutations in high-grade serous ovarian cancers
    Musaffe Tuna
    Zhenlin Ju
    Kosuke Yoshihara
    Christopher I. Amos
    Janos L. Tanyi
    Gordon B. Mills
    British Journal of Cancer, 2020, 122 : 405 - 412
  • [34] TP53 Mutation Is a Prognostic Factor in Lower Grade Glioma and May Influence Chemotherapy Efficacy
    Noor, Humaira
    Briggs, Nancy E.
    McDonald, Kerrie L.
    Holst, Jeff
    Vittorio, Orazio
    CANCERS, 2021, 13 (21)
  • [35] Identification and Validation of Prognostic Markers for Endometriosis-Associated Ovarian Cancer
    Yang, Huilin
    Deng, Yue
    Dong, Ying
    Ma, Yiqun
    Yang, Lihua
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2024, 21 (10): : 1903 - 1914
  • [36] Identification and prognostic analysis of metabolic genes associated with TP53 mutation in multiple myeloma
    Tang, Xiaoyan
    Chen, Yongping
    HEMATOLOGY, 2024, 29 (01)
  • [37] Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
    Boyarskikh, Ulyana A.
    Gulyaeva, L. F.
    Avdalyan, A. M.
    Kechin, A. A.
    Khrapov, E. A.
    Lazareva, D. G.
    Kushlinskii, N. E.
    Melkonyan, A.
    Arakelyan, A.
    Filipenko, Maxim Leonidovich
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [38] The differences in immunogenicity of TP53 mutated endometrial-, high-grade serous ovarian- and triple negative breast carcinomas
    Zeimet, A. G.
    Leitner, K.
    Hackl, H.
    Fiegl, H.
    Feroz, B.
    Marth, C.
    Steger, K.
    ANNALS OF ONCOLOGY, 2024, 35 : S591 - S591
  • [39] MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53
    Makii, Chinami
    Oda, Katsutoshi
    Ikeda, Yuji
    Sone, Kenbun
    Hasegawa, Kosei
    Uehara, Yuriko
    Nishijima, Akira
    Asada, Kayo
    Koso, Takahiro
    Fukuda, Tomohiko
    Inaba, Kanako
    Oki, Shinya
    Machino, Hidenori
    Kojima, Machiko
    Kashiyama, Tomoko
    Mori-Uchino, Mayuyo
    Arimoto, Takahide
    Wada-Hiraike, Osamu
    Kawana, Kei
    Yano, Tetsu
    Fujiwara, Keiichi
    Aburatani, Hiroyuki
    Osuga, Yutaka
    Fujii, Tomoyuki
    ONCOTARGET, 2016, 7 (46) : 75328 - 75338
  • [40] Prognostic relevance of gene signatures in high-grade serous ovarian carcinoma
    Konecny, Gottfried E.
    Wang, Chen
    Winterhoff, Boris
    Dering, Judy
    Ginther, Charles
    Chen, Hsiao-Wang
    Hamidi, Habib
    Podratz, Karl C.
    Cliby, William
    Dowdy, Sean Christopher
    Haluska, Paul
    Hartmann, Lynn C.
    Kalli, Kimberly
    Goode, Ellen L.
    Slamon, Dennis J.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345